Revance Therapeutics, Inc. Annual Interest Expense in USD from 2012 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of the cost of borrowed funds accounted for as interest expense.
Summary
Revance Therapeutics, Inc. quarterly/annual Interest Expense history and growth rate from 2012 to 2023.
  • Revance Therapeutics, Inc. Interest Expense for the quarter ending March 31, 2024 was $5.26M, a 16.9% increase year-over-year.
  • Revance Therapeutics, Inc. Interest Expense for the twelve months ending March 31, 2024 was $20.1M, a 5.65% increase year-over-year.
  • Revance Therapeutics, Inc. annual Interest Expense for 2023 was $19.4M, a 17.5% increase from 2022.
  • Revance Therapeutics, Inc. annual Interest Expense for 2022 was $16.5M, a 163% increase from 2021.
  • Revance Therapeutics, Inc. annual Interest Expense for 2021 was $6.27M, a 58.6% decline from 2020.
Interest Expense, Trailing 12 Months (USD)
Interest Expense, Annual (USD)
Interest Expense, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $19.4M +$2.88M +17.5% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-28
2022 $16.5M +$10.2M +163% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-28
2021 $6.27M -$8.88M -58.6% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-28
2020 $15.1M +$15.1M Jan 1, 2020 Dec 31, 2020 10-K 2023-02-28
2019 $0 -$44K -100% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-28
2018 $44K -$413K -90.4% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-25
2017 $457K -$625K -57.8% Jan 1, 2017 Dec 31, 2017 10-K 2020-02-26
2016 $1.08M -$108K -9.08% Jan 1, 2016 Dec 31, 2016 10-K 2019-02-28
2015 $1.19M -$9.48M -88.8% Jan 1, 2015 Dec 31, 2015 10-K 2018-03-02
2014 $10.7M -$4.49M -29.6% Jan 1, 2014 Dec 31, 2014 10-K 2017-02-28
2013 $15.2M +$14.7M +3315% Jan 1, 2013 Dec 31, 2013 10-K 2016-03-04
2012 $444K Jan 1, 2012 Dec 31, 2012 10-Q 2015-08-07
* An asterisk sign (*) next to the value indicates that the value is likely invalid.